A phase 2, randomized, double-blind study exploring the efficacy, safety and tolerability of tenofovir disoproxil fumarate (DF) [Viread] monotherapy versus emtricitabine plus tenofovir DF fixed-dose combination therapy [Truvada] in subjects currently being treated with adefovir dipivoxil [Hepsera] for chronic hepatitis B and having persistent viral replication.

Trial Profile

A phase 2, randomized, double-blind study exploring the efficacy, safety and tolerability of tenofovir disoproxil fumarate (DF) [Viread] monotherapy versus emtricitabine plus tenofovir DF fixed-dose combination therapy [Truvada] in subjects currently being treated with adefovir dipivoxil [Hepsera] for chronic hepatitis B and having persistent viral replication.

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Nov 2016

At a glance

  • Drugs Emtricitabine/tenofovir disoproxil fumarate (Primary) ; Tenofovir disoproxil fumarate (Primary)
  • Indications Hepatitis B
  • Focus Pharmacodynamics; Therapeutic Use
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 29 Nov 2013 Results published in the Journal of Hepatology.
    • 31 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 20 Jun 2010 Results have been published in Gastroenterology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top